Glaxosmithkline

This early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 18 years) whose solid tumors had come back or did not respond to treatment. The main goals were to find a safe dose and see how the drugs worked in the bod…

This early-stage study tested a new drug (GSK3965193) for chronic hepatitis B, first in healthy volunteers and then in people with the infection. Some participants also received a second drug (bepirovirsen). The goal was to check safety and how well the drugs lower the virus. The…

This study tested a new medicine called GSK3915393 for people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The trial aimed to see if the drug could slow lung function decline, but it was terminated early. About 15…

This study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could further reduce virus levels and improve the immune response. The t…

This early-stage study tested a single dose of an experimental drug called GSK4172239D in 11 adults with sickle cell disease. The goal was to check safety and how the drug moves through the body. The study was terminated early, so results are limited.

This study tested the long-term safety of an experimental drug called GSK1070806 in adults with moderate to severe atopic dermatitis (eczema). It was designed for people who had already completed an earlier study of the same drug. The study was terminated early, so only limited s…

This study tested an experimental injection called GSK1070806 in adults with moderate to severe eczema (atopic dermatitis) who had already tried other treatments. The goal was to see if it could reduce eczema severity and itching. The trial was terminated early, so results are li…

This study tested an experimental drug called GSK3858279 in 147 adults with long-term nerve pain caused by diabetes. The goal was to see if the drug could reduce daily pain better than a placebo. The trial was stopped early, so final results are limited, but the data may still he…

This study tested an experimental drug called GSK3858279 in 314 adults with moderate to severe knee osteoarthritis pain. The goal was to find the safest and most effective dose to reduce pain. The study was terminated early, but results may still help guide future research.

This study was the first to give GSK3494245 to humans, testing its safety and how the body processes it. It involved 59 healthy adults who received up to three doses of the drug or a placebo. The trial was terminated early, so results are limited.